Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 3/2008

01-06-2008

IgM Antibodies Against dsDNA in SLE

Author: Torsten Witte

Published in: Clinical Reviews in Allergy & Immunology | Issue 3/2008

Login to get access

Abstract

IgG antibodies against dsDNA are involved in the pathogenesis of systemic lupus erythematosus (SLE) glomerulonephritis. In contrast, glomerulonephritis is rare in SLE patients with IgM antibodies against dsDNA. Therefore, a possible protective effect of IgM antibodies has been studied in more detail. In murine models of SLE, the lack of secreted IgM was associated with more severe glomerulonephritis. In more recent studies, the treatment of lupus-prone mice with a murine IgM monoclonal antibody against dsDNA prevented renal damage. Furthermore, the clearance of pathogenic immune complexes may be improved by IgM. Therefore, IgM antibodies against dsDNA are indeed protective and may be a new treatment modality of lupus nephritis in humans.
Literature
1.
Wu JF, Yang YH, Wang LC, Lee JH, Shen EY, Chiang BL (2006) Antinucleosome antibodies correlate with the disease severity in children with systemic lupus erythematosus. J Autoimmun 27:119–124PubMedCrossRef
2.
Hylkema MN, van Bruggen MC, ten Hove T, de Jong J, Swaak AJ, Berden JH, Smeenk RJ (2000) Histone-containing immune complexes are to a large extent responsible for anti-dsDNA reactivity in the Farr assay of active SLE patients. J Autoimmun 14:159–168PubMedCrossRef
3.
Galeazzi M, Morozzi G, Piccini M, Chen J, Bellisai F, Fineschi S, Marcolongo R (2003) Dosage and characterization of circulating DNA: present usage and possible applications in systemic autoimmune disorders. Autoimmun Rev 2:50–55PubMedCrossRef
4.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640PubMedCrossRef
5.
Kippner L, Klint C, Sturfelt G, Bengtsson AA, Eriksson H, Truedsson L (2001) Increased level of soluble HLA class I antigens in systemic lupus erythematosus: correlation with anti-DNA antibodies and leukopenia. J Autoimmun 16:471–478PubMedCrossRef
6.
Putterman C (2004) New approaches to the renal pathogenicity of anti-DNA antibodies in systemic lupus erythematosus. Autoimmun Rev 3:7–11PubMedCrossRef
7.
Rekvig OP, Kalaaji M, Nossent H (2004) Anti-DNA antibody subpopulations and lupus nephritis. Autoimmun Rev 3:1–6PubMedCrossRef
8.
Nossent JC, Huysen V, Smeenk RJ, Swaak AJ (1989) Low avidity antibodies to double stranded DNA in systemic lupus erythematosus: a longitudinal study of their clinical significance. Ann Rheum Dis 48:677–682PubMedCrossRef
9.
Okamura M, Kanayama Y, Amastu K, Negoro N, Kohda S, Takeda T, Inoue T (1993) Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. Ann Rheum Dis 52:14–20PubMed
10.
Ghirardello A, Doria A, Zampieri S, Tarricone E, Tozzoli R, Villalta D, Bizzaro N, Piccoli A, Gambari PF (2004) Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients. J Autoimmun 22:235–240PubMedCrossRef
11.
Termaat RM, Assmann KJ, Dijkman HB, van Gompel F, Smeenk RJ, Berden JH (1992) Anti-DNA antibodies can bind to the glomerulus via two distinct mechanisms. Kidney Int 42:1363–1371PubMedCrossRef
12.
Sharma A, Isenberg DA, Diamond B (2001) Crossreactivity of human anti-dsDNA antibodies to phosphorylcholine: clues to their origin. J Autoimmun 16:479–484PubMedCrossRef
13.
Koren E, Koscec M, Wolfson-Reichlin M, Ebling FM, Tsao B, Hahn BH, Reichlin M (1995) Murine and human antibodies to native DNA that cross-react with the A and D SnRNP polypeptides cause direct injury of cultured kidney cells. J Immunol 154:4857–4864PubMed
14.
Ehrenstein MR, Katz DR, Griffiths MH, Griffiths MH, Papadaki L, Winkler TH, Kalden JR, Isenberg DA (1995) Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int 48:705–711PubMedCrossRef
15.
Mason LJ, Ravirajan CT, Latchman DS, Isenberg DA (2001) A human anti-dsDNA monoclonal antibody caused hyaline thrombi formation in kidneys of . ‘leaky’. SCID mice. Clin Exp Immunol 126:137–142PubMedCrossRef
16.
Tsao BP, Ohnishi K, Cheroutre H, Mitchell B, Teitell M, Mixter P, Kronenberg M, Hahn BH (1992) Failed self-tolerance and autoimmunity in IgG anti-DNA transgenic mice. J Immunol 149:350–358PubMed
17.
La Cava A, Fang CJ, Singh RP, Ebling F, Hahn BH (2005) Manipulation of immune regulation in systemic lupus erythematosus. Autoimmun Rev 4:515–519PubMedCrossRef
18.
Monneaux F, Muller S (2004) Peptide-based immunotherapy of systemic lupus erythematosus. Autoimmun Rev 3:16–24PubMedCrossRef
19.
20.
Witte T, Hartung K, Sachse C, Matthias T, Fricke M, Deicher H, SLE Study Group (1998) IgM anti-dsDNA antibodies in SLE: negative association with nephritis. Rheumatol Int 18:85–91PubMedCrossRef
21.
Forger F, Matthias T, Oppermann M, Becker H, Helmke K (2004) Clinical significance of anti-ds DNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus 13:36–44PubMedCrossRef
22.
Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J (2000) Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A 97:1184–1189PubMedCrossRef
23.
Ehrenstein MR, Cook HT, Neuberger MS (2000) Deficiency in serum immunoglobulin (Ig) M predisposes to development of IgG autoantibodies. J Exp Med 191:1253–1258PubMedCrossRef
24.
Werwitzke S, Trick D, Kamino K, Matthias T, Kniesch K, Schlegelberger B, Schmidt RE, Witte T (2005) Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse. Arthritis Rheum 52:3629–3638PubMedCrossRef
25.
Shoenfeld Y, Toubi E (2005) Protective autoantibodies: role in homeostasis, clinical importance, and therapeutic potential. Arthritis Rheum 52:2599–2606PubMedCrossRef
26.
Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR (2004) Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 199:1631–1640PubMedCrossRef
Metadata
Title
IgM Antibodies Against dsDNA in SLE
Author
Torsten Witte
Publication date
01-06-2008
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 3/2008
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-007-8046-x

Other articles of this Issue 3/2008

Clinical Reviews in Allergy & Immunology 3/2008 Go to the issue

OriginalPaper

Pemphigus: A Complex T Cell-dependent Autoimmune Disorder Leading to Acantholysis

OriginalPaper

Systemic Lupus Erythematosus Involving the Nervous System: Presentation, Pathogenesis, and Management

OriginalPaper

Pathways to ANCA Production: From Differentiation of Dendritic Cells by Proteinase 3 to B Lymphocyte Maturation in Wegener’s Granuloma

OriginalPaper

A Propos Time and Autoimmunity

OriginalPaper

Anti-α-Actinin Antibodies Cross-react with Anti-ssDNA Antibodies in Active Autoimmune Hepatitis

OriginalPaper

X Chromosome Inactivation and Female Predisposition to Autoimmunity
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits